Showing 1 - 10 of 18
Persistent link: https://www.econbiz.de/10003846596
In April 2003 a new payment system for hospitals called Payment by Results (PbR) was introduced in England. The new system is a fixed tariff case-mix based prospective payment system which reimburses hospitals for the type and amount of care they provide. By linking provider income more closely...
Persistent link: https://www.econbiz.de/10014049862
This report is a critique of the Centre for Health Economics Research Paper No. 81 (CHERP81), which estimates that the marginal cost of a QALY for the NHS in England in 2008/9 was £12,936. There is much to admire in the approach, detailed analysis, and reporting set out in CHERP81 and we...
Persistent link: https://www.econbiz.de/10014134103
Expenditure on medicines is a readily identifiable element of health service costs. As such, it is the focus of much attention by payers, not least in the UK despite the fact that the ex-manufacturer cost of medicines represents less than 10% of total UK National Health Service (NHS)...
Persistent link: https://www.econbiz.de/10013019275
Objectives: The objectives of this research were to identify the cost-effectiveness of health care services at the margin in the Scottish NHS; consider the extent to which the thresholds observed in Scottish NHS decision making are consistent with the threshold being used to make judgements...
Persistent link: https://www.econbiz.de/10013019353
Expenditure on medicines is a readily identifiable element of health service costs. As such, it is the focus of much attention by payers, not least in the UK despite the fact that the ex-manufacturer cost of medicines represents less than 10% of total UK National Health Service (NHS)...
Persistent link: https://www.econbiz.de/10013019358
Persistent link: https://www.econbiz.de/10013029405
Persistent link: https://www.econbiz.de/10003306100
Knowing the net value that companies, or whole sectors of the economy, bring is clearly important when considering economic and industrial policy. In this paper we estimate the economic contribution to the UK made by two British based, research intensive, pharmaceutical companies: AstraZeneca...
Persistent link: https://www.econbiz.de/10013017910
Competition is firmly established as a tool of public policy in England and is being accorded a growing role within health care. Since 2002 competition has become an actively promoted tool of government health care policy in England, particularly for the provision of hospital care to publicly...
Persistent link: https://www.econbiz.de/10013018106